FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Pharmaceutical Executive
Pharmaceutical Executive Daily: FDA Approves New Indication for Kerendia
Pharmaceutical Executive Daily: Novo Partners with Anthropic
Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership
Pharmaceutical Executive Daily: Novo Nordisk Enters Rebrand
Get summaries like this every morning.
Free AI-powered recaps of Pharmaceutical Executive and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.